Citations

Clear

6273 citation(s) found for "To, Andrew".

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
Abdelmessieh, Peter, Ali, Haris , Dunbar, Andrew , Revell, Rebecca, Green, Steven D. , Gundabolu, Krishna , Jamieson, Catriona, Kaesberg, Paul, Madanat, Yazan F. , Manchanda, Naveen, McMahon, Brandon , Nadiminti, Kalyan , Palmer, Jeanne , Patel, Anand , Rein, Lindsay , Salit, Rachel B. , Wadleigh, Martha , Wall, Sarah , Bergman, Mary Anne, Hochstetler, Cindy, Patel, Anand , Madanat, Yazan , Gotlib, Jason , Gerds, Aaron T. , Castells, Mariana , George, Tracy I. , Hexner, Elizabeth O. , Jain, Tania , Kuykendall, Andrew , Masárová, Lucia , May, Jori E. , Mohan, Sanjay , Oh, Stephen T. , Patel, Ami B. , Podoltsev, Nikolai , Talpaz, Moshe

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2024 | Volume: 22 | Issue: 2D | Pages: No page available

10.6004/jnccn.2024.0030 | PMID 38862005 Get It

Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Referral to specialized centers with expertise in the management of mastocytosis and multidisciplinary collaboration with subspecialists (eg, allergists for the management of anaphylaxis and drug hypersensitivities, anesthesiologists for invasive procedures or surgery, high-risk obstetrician for pregnancy) is recommended. The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.
Differences in perceived energy and macronutrient requirements across divisions in NCAA athletes
Singleton, Kimberly Michelle , McAllister-Deitrick, Jamie, Daou, Marcos , Kerksick, Chad M. , Singleton, K Michelle , Jagim, Andrew R , Kerksick, Chad M , Jagim, Andrew R.

Mayo Clinic

Journal of the International Society of Sports Nutrition | June 11, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1080/15502783.2024.2365307 | PMID 38860870 Get It

Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer’s disease
Tu, Jiaxin Cindy , Millar, Peter R , Strain, Jeremy F. , Eck, Andrew, Adeyemo, Babatunde, Daniels, Alisha , Huey, Edward D. , Day, Gregory S. , Hassenstab, Jason , Méndez, Patricio Chrem, Perrin, Richard J. , Jack, Clifford R. , Betzel, Richard F. , Wheelock, Muriah D. , Network, the Dominantly Inherited Alzheimer, Wheelock, Muriah D , Jack, Clifford R , Day, Gregory S , Hassenstab, Jason , Daniels, Alisha, Karch, Celeste M. , Huey, Edward D., McDade, Eric, Igor, Yakushev, Hassenstab, Jason, Morris, John, Llibre‐Guerra, Jorge J. , Ibanez, Laura , Jucker, Mathias , Bateman, Randall J. , Benzinger, Tammie L.S. , Ances, Beau M. , Eggebrecht, Adam T. , Gordon, Brian A. , (DIAN), The Dominantly Inherited Alzheimer Network

Mayo Clinic

Network Neuroscience | June 11, 2024 | Volume: 8 | Issue: 4 | Pages: 1265-1290

10.1162/netn_a_00395 | PMID 39735502 Get It

Abstract Hub regions in the brain, recognized for their roles in ensuring efficient information transfer, are vulnerable to pathological alterations in neurodegenerative conditions, including Alzheimer’s disease (AD). Computational simulations and animal experiments have hinted at the theory of activity-dependent degeneration as the cause of this hub vulnerability. However, two critical issues remain unresolved. First, past research has not clearly distinguished between two scenarios: hub regions facing a higher risk of connectivity disruption (targeted attack) and all regions having an equal risk (random attack). Second, human studies offering support for activity-dependent explanations remain scarce. We refined the hub disruption index to demonstrate a hub disruption pattern in functional connectivity in autosomal dominant AD that aligned with targeted attacks. This hub disruption is detectable even in preclinical stages, 12 years before the expected symptom onset and is amplified alongside symptomatic progression. Moreover, hub disruption was primarily tied to regional differences in global connectivity and sequentially followed changes observed in amyloid-beta positron emission tomography cortical markers, consistent with the activity-dependent degeneration explanation. Taken together, our findings deepen the understanding of brain network organization in neurodegenerative diseases and could be instrumental in refining diagnostic and targeted therapeutic strategies for AD in the future.
Short‐term outcomes of surgical treatment for primary ileocaecal Crohn's disease: Results of the Crohn's(urg) study, a multicentre, retrospective, comparative analysis between inflammatory and complicated phenotypes
Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Bislenghi, Gabriele , Colpaert, Jan , D’Hoore, André , Giorgi, Lorenzo , Juachon, Patrizia, Harsløf, Sanne , Overstraeten, Anthony de Buck van , Merchea, Amit , Shaker, Andrew, Maruyama, Beatriz Yuki , Wexner, Steven D. , Garoufalia, Zoe , Chen, Zhihui , Rrupa, Djana , Haanappel, Anouck , Potolicchio, Analia, Spinelli, Antonino , Bislenghi, Gabriele , Colpaert, Jan , Harsløf, Sanne , Holubar, Stefan D , Merchea, Amit , Wexner, Steven D , Spinelli, Antonino , Tottrup, Anders, Carvello, Michele , Olivera, Pablo Andres , Gomez, Javier, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Martí, Marc , Kraft, Miquel , Kotze, Paulo Gustavo , Chen, Zhihui, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, Katherine J., Christensen, Peter , Wolthuis, Albert M.

Mayo Clinic

Colorectal Disease | June 10, 2024 | Volume: 26 | Issue: 7 | Pages: 1415-1427

10.1111/codi.17056 | PMID 38858815 Get It

Abstract Aim Recent evidence challenges the current standard of offering surgery to patients with ileocaecal Crohn's disease (CD) only when they present complications of the disease. The aim of this study was to compare short‐term results of patients who underwent primary ileocaecal resection for either inflammatory (luminal disease, earlier in the disease course) or complicated phenotypes, hypothesizing that the latter would be associated with worse postoperative outcomes. Method A retrospective, multicentre comparative analysis was performed including patients operated on for primary ileocaecal CD at 12 referral centres. Patients were divided into two groups according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short‐term results were compared. Results A total of 2013 patients were included, with 291 (14.5%) in the ICD group. No differences were found between the groups in time from diagnosis to surgery. CCD patients had higher rates of low body mass index, anaemia (40.9% vs. 27%, p < 0.001) and low albumin (11.3% vs. 2.6%, p < 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3% vs. 93.1%, p = 0.001) and higher conversion rates (9.3% vs. 1.9%, p < 0.001). CCD patients had a longer hospital stay and higher postoperative complication rates (26.1% vs. 21.3%, p = 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1% vs. 8.3%, p : 0.017). In multivariate analysis, CCD was associated with prolonged surgery (OR 3.44, p = 0.001) and the requirement for multiple intraoperative procedures (OR 8.39, p = 0.030). Conclusion Indication for surgery in patients who present with an inflammatory phenotype of CD was associated with better outcomes compared with patients operated on for complications of the disease. There was no difference between groups in time from diagnosis to surgery.
Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Ansell, Stephen M. , Straus, David J. , Kim, Won-Seog, Gallamini, Andrea , Ramchandren, Radhakrishnan , Friedberg, Jonathan W. , Eom, Hyeon‐Seok , Feldman, Tatyana , Dong, Cassie, Zomas, Athanasios, Fenton, Keenan , Connors, Joseph M. , Jurczak, Wojciech , Advani, Ranjana H. , Hutchings, Martin , Evens, Andrew M. , Savage, Kerry J. , Abramson, Jeremy S. , Savani, Bipin N. , Radford, John

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7053-7053

10.1200/jco.2024.42.16_suppl.7053 Get It

7053 Background: In ECHELON-1 (NCT01712490), 6-year follow-up (FU) analyses demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) with A+AVD (brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), with a comparable safety profile. Here, we report data at 7-year median FU. Methods: Analyses of OS and PFS per investigator were conducted in the intent-to-treat (ITT) population (data cut-off March 11, 2023). Patients (pts) were randomized 1:1 to receive ≤6 cycles of A+AVD (n=664) or ABVD (n=670) on days 1 and 15, every 28 days. PET scan after cycle 2 (PET2) evaluation was mandatory. Long-term safety outcomes in the safety population included resolution or improvement of peripheral neuropathy (PN), second malignancies, and pregnancies. Results: At median FU of 89.3 months (95% CI 87.0–90.2), 7-year OS rates were 93.5% (95% CI 91.1–95.2) with A+AVD and 88.8% (95% CI 85.8–91.1) with ABVD; OS favored A+AVD over ABVD (HR 0.62; 95% CI 0.42–0.90; p=0.011). Subgroup analyses showed consistent OS benefit for A+AVD, including in the age <40 years and Stage IV disease subgroups (Table). 7-year PFS rates with A+AVD vs ABVD were 82.3% (95% CI 79.1–85.0) vs 74.5% (95% CI 70.8–77.7; HR 0.68 [95% CI 0.53–0.86]; p=0.001). PN improved/resolved in most pts at last FU (A+AVD: 86%; ABVD: 87%). Median (range) time to complete resolution of PN (A+AVD vs ABVD) was 16 (0–373) vs 10 (0–343) weeks; median (range) time to improvement was 42 (2–182) vs 19 (15–142) weeks. PN was ongoing in 28% (4% grade ≥3) of A+AVD and 20% (1% grade ≥3) of ABVD pts. Second malignancies were reported in 5% of A+AVD and 6% of ABVD pts. Pts and their partners reported 84/92 livebirths/pregnancies with A+AVD and 59/73 with ABVD; no stillbirths were recorded. Conclusions: At 7-year median FU, pts with stage III/IV cHL who received A+AVD showed a sustained PFS and OS benefit vs ABVD, with PFS rates indicating potential curability. The safety profile in pts treated with A+AVD showed no new safety signals at 7 years. Clinical trial information: NCT01712490 . [Table: see text]
Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity
Francoeur, Conall , Robertson, Courtney , Wainwright, Mark S. , Roa, Juan D. , Lovett, Marlina E. , Stulce, Casey , Yacoub, M, Potera, Renee M. , Zivick, Elizabeth, Holloway, Adrian , Nagpal, Ashish, Even, Katelyn , Rodriguez, Isadora Souza , Walker, Tracie C. , Campos-Miño, Santiago , Sewell, Taylor B. , Pryce, Patrice , Silver, Wendy G. , Lin, Jieru E. , Vargas, Wendy , McGuire, Jennifer L. , Tasayco-Muñoz, Jaime , Hong, Sue J. , Doerfler, Matthew , Williams, Cydni N. , Drury, Kurt , Bhagat, Dhristie, Price, Dana C. , Santos, Laura Jurema dos , Kahoud, Robert J., Agner, Shannon C. , Walson, Karen, Rasmussen, Lindsey , Pal, Ria , Janas, Anna , Ferrazzano, Peter , Farias‐Moeller, Raquel , Snooks, Kellie , Chang, Chung‐Chou H. , Iolster, Tomás, Erklauer, Jennifer , Yoong, Michael , Jardine, Michelle, Mohammad, Zoha, Deep, Akash , Kendirli, Tanıl , Lidsky, Karen , Dallefeld, Samantha , Flockton, Helen, Agrawal, Shruti , Siruguppa, K., Gutiérrez-Mata, Alfonso, Bogantes-Ledezma, Sixto , Sevilla-Acosta, Fabricio , Umaña-Calderón, Andrés , Ulate-Campos, Adriana , Talisa, Victor B. , Kanthimathinathan, Hari Krishnan , Schober, Michelle E. , Kahoud, Robert, Wainwright, Mark S , Alcamo, Alicia M. , Yacoub, Mais, Wellnitz, Kari , Carvalho, Werther Brunow de , Schwartz, Stephanie P. , Dervan, Leslie A. , Geneslaw, Andrew S. , Topjian, Alexis , Domínguez-Rojas, Jesús , Muller, William J. , Nelson, Aaron L.A. , Price, Dana, Dapul, Heda , Appavu, Brian , Guilliams, Kristin P. , Barón, Facundo Jorro , Wassmer, Evangeline , Waak, Michaela , Butt, Warwick W. , Yock‐Corrales, Adriana , Fink, Ericka L.

Mayo Clinic

JAMA Network Open | June 10, 2024 | Volume: 7 | Issue: 6 | Pages: e2414122

10.1001/jamanetworkopen.2024.14122 | PMID 38857050 Get It

Importance Neurological manifestations during acute SARS-CoV-2–related multisystem inflammatory syndrome in children (MIS-C) are common in hospitalized patients younger than 18 years and may increase risk of new neurocognitive or functional morbidity. Objective To assess the association of severe neurological manifestations during a SARS-CoV-2–related hospital admission with new neurocognitive or functional morbidities at discharge. Design, Setting, and Participants This prospective cohort study from 46 centers in 10 countries included patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C between January 2, 2020, and July 31, 2021. Exposure Severe neurological manifestations, which included acute encephalopathy, seizures or status epilepticus, meningitis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke. Main Outcomes and Measures The primary outcome was new neurocognitive (based on the Pediatric Cerebral Performance Category scale) and/or functional (based on the Functional Status Scale) morbidity at hospital discharge. Multivariable logistic regression analyses were performed to examine the association of severe neurological manifestations with new morbidity in each SARS-CoV-2–related condition. Results Overall, 3568 patients younger than 18 years (median age, 8 years [IQR, 1-14 years]; 54.3% male) were included in this study. Most (2980 [83.5%]) had acute SARS-CoV-2; the remainder (588 [16.5%]) had MIS-C. Among the patients with acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as did 146 patients with MIS-C (24.8%). Among survivors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new neurocognitive or functional morbidity at hospital discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n = 356]; P &amp;lt; .001). For survivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/or functional morbidity at hospital discharge compared with 15.5% (n = 68) of those without severe neurological manifestations ( P = .002). When adjusting for risk factors in those with severe neurological manifestations, both patients with acute SARS-CoV-2 (odds ratio, 1.85 [95% CI, 1.27-2.70]; P = .001) and those with MIS-C (odds ratio, 2.18 [95% CI, 1.22-3.89]; P = .009) had higher odds of having new neurocognitive and/or functional morbidity at hospital discharge. Conclusions and Relevance The results of this study suggest that children and adolescents with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101).
Reimers, Melissa A. , Laccetti, Andrew Leonard , Ravi, Praful , Dooley, Katharine , Gartrell, Benjamin A. , Steen, Preston D. , Baghaie, Shiva, Ajmera, Archana , Beltran, Himisha , McKay, Rana R. , Galsky, Matt D., Choudhury, Atish D. , Heller, Glenn , Smieliauskas, Fabrice , Mazza, Gina L , Kroll, Kayla, Smith, Thomas J. , Chen, Ronald C. , Rosenberg, Jonathan E , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS5118-TPS5118

10.1200/jco.2024.42.16_suppl.tps5118 Get It

TPS5118 Background: Novel androgen receptor pathway inhibitors (ARPIs) improve overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in conjunction with testosterone suppression (TS) relative to TS alone. However, the duration of treatment required to derive clinical benefit is unclear, as is whether continuous treatment is requisite for optimal cancer outcomes. Favorable PSA declines have been associated with prolonged OS in clinical trials testing TS + ARPIs. We thus designed this single-arm Phase 2 trial to test the hypothesis that pts who achieve exceptional response to upfront TS + ARPI can suspend treatment, allowing for T recovery and improvement in quality of life while maintaining favorable clinical outcomes. Methods: Eligible pts had mHSPC by conventional imaging with PSA ≥ 5 ng/ml and T ≥ 150 ng/dl (or not known to have been hypogonadal) prior to starting treatment, have been receiving TS for 540-750 days and ARPI for ≥ 360 days, and have achieved PSA < 0.2 ng/ml (stable or falling for 3 consecutive measurements) with castrate T <50 ng/dl at the time of enrollment. Intermittent ADT for biochemical recurrence prior to mHSPC diagnosis, prior local therapy, prior radiation to metastatic sites, and up to 6 cycles of docetaxel in mHSPC are permitted. Pts who underwent surgical castration, received ARPI prior to mHSPC diagnosis, or are receiving experimental treatment for mHSPC or participating in a clinical trial that does not allow for TS or ARPI interruption are excluded. After enrollment, pts discontinue both TS and ARPI and are followed with PSA and T levels every 3 months, conventional CT/MRI and bone scan at least every 6 months, and FACT-P questionnaire for patient-reported outcomes every 6 months. Treatment re-initiation triggers are PSA increase to ≥ 5 ng/ml, radiographic change (progressive disease per modified RECIST 1.1 on CT/MRI or unconfirmed progressive disease per PCWG3 on bone scan), or symptoms attributable to prostate cancer. Subsequent management is per physician discretion. The primary endpoint is remaining treatment-free with eugonadal T (> 150 mg/dl) 18 months after the start of treatment interruption, with 75 pts to be enrolled to differentiate 18-month treatment free rates of 0.30 (null hypothesis) and 0.45 (alternative hypothesis). Secondary endpoints include time to eugonadal T, duration off treatment, and changes in patient-reported outcomes. Exploratory endpoints include radiographic progression-free survival, time to next treatment, OS, and correlation of tissue- and blood-based biomarkers with clinical endpoints. The study was activated in July 2022 and accrual is ongoing throughout the NCTN. Support: U10CA180821, U10CA180882, UG1CA189823, https://acknowledgments.alliancefound.org , Veracyte Inc. Clinical trial information: NCT05241860 .
Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.
Calais, Jérémie , Murthy, Vishnu , Nguyen, Kathleen, Allen-Auerbach, Martin , Caputo, Sydney , Akerele, Opeoluwa Abraham, Tuchayi, Abuzar Moradi, Czernin, Johannes, Sólnes, Lilja B. , Gafita, Andrei , Calais, Jeremie , Voter, Andrew F. , Ledet, Elisa M. , Lawhn-Heath, Courtney A. , Carducci, Michael A. , Pomper, Martin G. , Paller, Channing J. , Hope, Thomas A. , Sartor, Oliver

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e17061-e17061

10.1200/jco.2024.42.16_suppl.e17061 Get It

e17061 Background: ThePhase 3 VISION trial demonstrated that [177Lu]Lu-PSMA-617 prolonged overall survival (OS) in metastatic-castration resistant prostate cancer (mCRPC) patients who progressed on taxane-based chemotherapy and androgen receptor-signaling inhibitors (ARSi). The expanded access program (EAP) (NCT04825652) was opened to provide access to [177Lu]Lu-PSMA-617 for eligible patients until regulatory approval was obtained. The VISION trial required strict inclusion and exclusion criteria, which may not represent the patient population encountered in clinical practice. This study aimed to evaluate the efficacy and safety profile of [177Lu]Lu-PSMA-617 in a real-world setting within the EAP and compare the results with those from the VISION trial. Methods: Patients enrolled in the EAP between May 2021 and March 2022 at four institutions in the United States with available toxicity and outcome data were included. Outcome measures included overall survival (OS), ≥50% PSA decline rates (PSA-RR), and incidences of toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Differences in baseline characteristics, toxicity, and PSA-RR between the EAP and VISION were evaluated using a t-test of proportions. Results: 117 patients with mCRPC were eligible and included. Patients enrolled in the EAP were similarly pretreated with taxane-based chemotherapy regimens (>1 taxane: 47% vs 40%; p=0.16) and more heavily pretreated with ARSi (>1 ARSi: 70% vs 46%; p<0.001). EAP patients had similar levels of ≥3 grade anemia (18% vs 13%; p=0.15), thrombocytopenia (13% vs 8%; p=0.13), and neutropenia (3% vs 3%; p=0.85) and higher levels of ≥3 grade lymphopenia (34% vs 8%; p<0.001). Patients treated within the EAP experienced numerically shorter OS (median OS: 13.7 vs 15.3 months) and similar PSA-RR (40% vs 46%; p=0.29). Median follow-up was numerically shorter in the EAP compared with VISION (14.7 mo vs 20.3 mo). Conclusions: mCRPC patients treated with [177Lu]Lu-PSMA-617 in a real-world setting were more heavily pretreated with ARSi, had a similar safety profile, and experienced numerically shorter OS and similar PSA-RR compared with VISION trial patients. A major limitation of this study is that we did not have access to individual patient data from the VISION trial, so we were not able to assess whether differences in OS between VISION and the EAP were statistically significant.
Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
Hanin, Aurélie , Jimenez, Anthony D. , Asbell, Hannah, Aydemir, Seyhmus, Basha, Maysaa , Batra, Ayush , Damien, Charlotte , Day, Gregory S. , Eka, Onome , Eschbach, Krista , Fatima, Safoora , Fields, Madeline , Haider, Hiba A. , Hantus, Stephen , Hocker, Sara E. , Aparicio, Mariel Kalkach , Kandula, Padmaja , Kang, Peter , Kim, Minjee , Marcuse, Lara , Mohamed, Wazim, Orozco, Janet, Pimentel, Cederic M., Punia, Vineet , Taraschenko, Olga , Treister, Andrew , Wainwright, Mark S. , Yoo, Ji Yeoun , Zafar, Sahar F. , Zhou, Daniel J. , Zutshi, Deepti , Gaspard, Nicolas , Basha, Maysaa M , Batra, Ayush , Eschbach, Krista , Gofton, Teneille E , Haider, Hiba A , Hocker, Sara, Kalkach Aparicio, Mariel , Kandula, Padmaja , Lee, Jong Woo , Mohamed, Wazim , Punia, Vineet , Taraschenko, Olga , Yoo, Ji Yeoun , Zafar, Sahar , Zutshi, Deepti , Hirsch, Lawrence J , Wainwright, Mark S , Gaspard, Nicolas , Day, Gregory S , Hanin, Aurelie , Kim, Minjee , Gopaul, Margaret , Foreman, Brandon , Gerard, Elizabeth E. , Gofton, Teneille , Jongeling, Amy , Kazazian, Karnig , Kellogg, Marissa , McGraw, Christopher Michael , Ramirez, Alexandra M., Steriade, Claude , Struck, Aaron F. , Hirsch, Lawrence J.

Mayo Clinic

Epilepsia | June 5, 2024 | Volume: 65 | Issue: 8 | Pages: No page available

10.1111/epi.18014 | PMID 38837761 Get It

AbstractIn response to the evolving treatment landscape for new‐onset refractory status epilepticus (NORSE) and the publication of consensus recommendations in 2022, we conducted a comparative analysis of NORSE management over time. Seventy‐seven patients were enrolled by 32 centers, from July 2016 to August 2023, in the NORSE/FIRES biorepository at Yale. Immunotherapy was administered to 88% of patients after a median of 3 days, with 52% receiving second‐line immunotherapy after a median of 12 days (anakinra 29%, rituximab 25%, and tocilizumab 19%). There was an increase in the use of second‐line immunotherapies (odds ratio [OR] = 1.4, 95% CI = 1.1–1.8) and ketogenic diet (OR = 1.8, 95% CI = 1.3–2.6) over time. Specifically, patients from 2022 to 2023 more frequently received second‐line immunotherapy (69% vs 40%; OR = 3.3; 95% CI = 1.3–8.9)—particularly anakinra (50% vs 13%; OR = 6.5; 95% CI = 2.3–21.0), and the ketogenic diet (OR = 6.8; 95% CI = 2.5–20.1)—than those before 2022. Among the 27 patients who received anakinra and/or tocilizumab, earlier administration after status epilepticus onset correlated with a shorter duration of status epilepticus (ρ = .519, p = .005). Our findings indicate an evolution in NORSE management, emphasizing the increasing use of second‐line immunotherapies and the ketogenic diet. Future research will clarify the impact of these treatments and their timing on patient outcomes.
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
Trotter, Chardria, Jackson, Vicki A. , Rinaldi, Simone , Kamdar, Mihir , El‐Jawahri, Areej , Pintro, Kedie, Rabideau, Dustin J. , Feliciano, Josephine , Leventakos, Konstantinos , Rabow, Michael W. , Zachariah, Finly , Martin, Sara , Silveira, Maria J. , Greer, Joseph Andrew , Horick, Nora , Pintro, Kedie, Chua, Isaac S. , Fischer, Stacy M. , Campbell, Toby C. , Hanson, Laura C. , Temel, Jennifer S.

Mayo Clinic

Journal of Clinical Oncology | June 5, 2024 | Volume: 42 | Issue: 17_suppl | Pages: LBA3-LBA3

10.1200/jco.2024.42.17_suppl.lba3 Get It

LBA3 Background: National guidelines recommend the early integration of palliative and oncology care for patients with advanced cancer, given robust evidence showing that this care model improves quality of life (QOL) and other important outcomes. However, most patients do not receive early palliative care (EPC) in the outpatient setting due to limited access and resources. To overcome these barriers, we conducted a large-scale comparative effectiveness trial of EPC delivered via secure video versus in person among patients with advanced non-small cell lung cancer (NSCLC) and their caregivers. Methods: Between 6/14/2018 and 5/4/2023, we enrolled 1250 patients with advanced NSCLC, diagnosed in the past 12 weeks, into a randomized trial of telehealth versus in-person EPC across 22 cancer centers in the US. Patients were randomly assigned to meet with a palliative care clinician every four weeks from enrollment through the course of disease either via video or in the outpatient clinic. Participants completed self-report measures at baseline and weeks 12 and 24. The primary aim was to evaluate the equivalence of the effect of telehealth versus in-person EPC on QOL at week 24, using regression modeling with an equivalence margin of ±4 points on the Functional Assessment of Cancer Therapy-Lung (FACT-L, range = 0-136). We also compared rates of caregiver participation in EPC visits and patient-reported depression and anxiety symptoms (Patient Health Questionnaire-9; Hospital Anxiety and Depression Scale), coping (Brief COPE), and perceptions of prognosis (Perceptions of Treatment and Prognosis Questionnaire) between groups. Study recruitment ceased for two months at the onset of the COVID-19 pandemic. Results: Participants (mean age = 65.5 years; 54.0% female; 82.1% White) had a mean of 4.75 and 4.92 palliative care encounters by week 24 in the telehealth and in-person groups, respectively. Due to the pandemic, the in-person group had 3.9% of visits occur via video. QOL scores at week 24 for patients assigned to the telehealth group were equivalent to those receiving in-person EPC (adjusted means: 99.67 versus 97.67, p < 0.043 for equivalence). The rate of caregiver participation in EPC visits was lower in the telehealth versus in-person group (36.6% versus 49.7%, p < 0.0001). Study groups did not differ in depression and anxiety symptoms, use of coping skills, or perceptions of the goal of treatment and curability of their cancer. Conclusions: The delivery of EPC via video versus in-person visits demonstrated equivalent effects on QOL in patients with advanced NSCLC. The two modalities also did not differ across a range of patient-reported outcomes, though caregivers attended more in-person versus video visits. The findings underscore the considerable potential for improving access to and broader dissemination of this evidence-based care model through telehealth delivery. Clinical trial information: NCT03375489 .